AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30893645 — intervention group
Group type: COMPARATOR
Intervention: LFHCC control
Number of subjects: 486
Study 30893645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diets (HSFA and HMUFA)
Number of subjects: 486
Study 28629872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane administered at 1 minimal alveolar concentration for 5 minutes after being weaned from CPB (group SEV)
Number of subjects: 190
Study 28629872 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthesia maintained (group CTRL)
Number of subjects: 190
Study 26403536 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 1004
Study 26403536 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 1004
Study 23412700 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat (1.6 mg dose group)
Number of subjects: 9
Study 23412700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 23412700 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat (estimated dose of 18 μg/mL)
Number of subjects: 9
Study 23412700 — intervention group
Group type: COMPARATOR
Intervention: Camostat and Placebo
Number of subjects: 9
Study 21948536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis procedure (n=116)
Number of subjects: 232
Study 21948536 — intervention group
Group type: COMPARATOR
Intervention: Sweet procedure (n=116)
Number of subjects: 232
Study 21948536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis procedure
Number of subjects: 232
Study 21948536 — intervention group
Group type: COMPARATOR
Intervention: Sweet procedure
Number of subjects: 232
Study 19445719 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 25
Study 19445719 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS laryngoscope
Number of subjects: 25
Study 19445719 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 25
Study 17386280 — intervention group
Group type: EXPERIMENTAL
Intervention: Top hat-shaped PKP using a femtosecond laser
Number of subjects: 14
Study 17386280 — intervention group
Group type: COMPARATOR
Intervention: Traditional PKP
Number of subjects: 14
Study 15359920 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-pipe smokers (WPS)
Number of subjects: 25
Study 15359920 — intervention group
Group type: COMPARATOR
Intervention: Passive smokers (PS)
Number of subjects: 25
Study 11394515 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg fentanyl (0.4 ml)
Number of subjects: 52
Study 11394515 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (0.4 ml)
Number of subjects: 52
Study 9972118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial-dose doxycycline (SDD) 20 mg BID
Number of subjects: 0
Study 8071758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin A supplementation
Number of subjects: 51
Study 8071758 — intervention group
Group type: COMPARATOR
Intervention: Enteral vitamin A supplementation
Number of subjects: 51
Study 3179171 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg every 6 h for 7 days)
Number of subjects: 8
Study 3179171 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin sodium (400 mg single oral dose)
Number of subjects: 8
Study 5309085 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct BCG vaccination
Number of subjects: 0
Study 5309085 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different vaccines
Number of subjects: 0
Study 31443102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 × 10^10 CFU B. infantis EVC001 daily for 21 days
Number of subjects: 120
Study 31443102 — intervention group
Group type: COMPARATOR
Intervention: Breast milk alone (controls)
Number of subjects: 120
Study 28421383 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine XR 1 mg orally on Day 1, followed by 1 mg (Days 4-8), 2 mg (Days 9-13), 3 mg (Days 14-18), and 4 mg (Days 19-23) once daily
Number of subjects: 30
Study 28421383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25966824 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, formula-based dosing of Genotropin®
Number of subjects: 0
Study 25966824 — intervention group
Group type: COMPARATOR
Intervention: Standard weight-based dosing of Genotropin®
Number of subjects: 0
Study 24088130 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing (genetic plus clinical information)
Number of subjects: 109
Study 24088130 — intervention group
Group type: COMPARATOR
Intervention: Clinical information only
Number of subjects: 109
Study 21315341 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH bolus at time of hCG trigger
Number of subjects: 188
Study 21315341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 19371312 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (0.2 mg)
Number of subjects: 12
Study 16877722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated infusion of fluorouracil, leucovorin, and oxaliplatin for 4 days (chronoFLO4)
Number of subjects: 564
Study 16877722 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2-day delivery of fluorouracil, leucovorin, and oxaliplatin (FOLFOX2)
Number of subjects: 564
Study 16877722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated infusion (chronoFLO4) in women
Number of subjects: 564
Study 16877722 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated infusion (chronoFLO4) in men
Number of subjects: 564
Study 15522472 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure of PDA with coils
Number of subjects: 70
Study 10902785 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI (1/[log(I(0)) + log(G(0))])
Number of subjects: 56
Study 10902785 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 56
Study 9076577 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol treatment
Number of subjects: 58
Study 9076577 — intervention group
Group type: COMPARATOR
Intervention: Before calcitriol treatment
Number of subjects: 58
Study 9076577 — intervention group
Group type: COMPARATOR
Intervention: Residual values of set point (PTHstim) before calcitriol
Number of subjects: 58
Study 9076577 — intervention group
Group type: COMPARATOR
Intervention: Residual values of set point (PTHstim) after calcitriol
Number of subjects: 58
Study 8222495 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice a day for 2 weeks after 1 week of placebo or indomethacin
Number of subjects: 12
Study 8222495 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice a day for 2 weeks after 1 week of placebo or indomethacin
Number of subjects: 12
Study 8222495 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg twice a day for 3 weeks
Number of subjects: 12
Study 8222495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3513075 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-epi-DX + 5-FU
Number of subjects: 62
Study 3513075 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 62
Study 30047574 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 1240
Study 30047574 — intervention group
Group type: COMPARATOR
Intervention: No catheter ablation (CA)
Number of subjects: 1240
Study 26784336 — intervention group
Group type: EXPERIMENTAL
Intervention: Water jets installation in schools
Number of subjects: 1065562
Study 24613404 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound-guided RFVTA
Number of subjects: 135
Study 22772051 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieve inner lumen mapping catheter
Number of subjects: 40
Study 22772051 — intervention group
Group type: COMPARATOR
Intervention: Circular mapping catheter
Number of subjects: 40
Study 20347564 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 42
Study 20347564 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 42
Study 20347564 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 42
Study 20347564 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA CTrach
Number of subjects: 42
Study 20347564 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 42
Study 18672472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine 10 mg twice daily
Number of subjects: 206
Study 18672472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine 15 mg twice daily
Number of subjects: 206
Study 18672472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine 20 mg twice daily
Number of subjects: 206
Study 18672472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 15906951 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) (n=139)
Number of subjects: 345
Study 15906951 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus 5 mg medroxyprogesterone acetate (MPA) (n=97)
Number of subjects: 345
Study 15906951 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus 10 mg MPA (n=109)
Number of subjects: 345
Study 15906951 — intervention group
Group type: COMPARATOR
Intervention: Control group (BMI <25 Kg/m2)
Number of subjects: 345
Study 15906951 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group (BMI >=25 Kg/m2)
Number of subjects: 345
Study 12888586 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg/day for 3 days
Number of subjects: 373
Study 12888586 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav 45 mg/kg/day for 10 days
Number of subjects: 373
Study 11270004 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0
Study 11270004 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study 9753705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg i.v.
Number of subjects: 32
Study 9753705 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine N-butylbromide 20 mg i.v.
Number of subjects: 32
Study 7910470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg suriclone
Number of subjects: 15
Study 7910470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg suriclone
Number of subjects: 15
Study 7910470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg suriclone
Number of subjects: 15
Study 7910470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 15
Study 7910470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7910470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg) vs Suriclone (0.4 mg)
Number of subjects: 15
Study 3111101 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose dexamethasone
Number of subjects: 16
Study 3111101 — intervention group
Group type: EXPERIMENTAL
Intervention: Double doses of dexamethasone
Number of subjects: 16
Study 30909787 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intra‐arterial prostaglandin therapy
Number of subjects: 32
Study 30909787 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention
Number of subjects: 32
Study 31160549 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (Arm 1: 0.2 mg/kg/day, Arm 2: 0.15-0.175 mg/kg/day, Arm 3: 0.2 mg/kg/day delayed until Day 5)
Number of subjects: 844
Study 31160549 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (early lower-dose and delayed higher-dose regimens)
Number of subjects: 844
Study 31160549 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (early-lower tacrolimus arm with older donors, delayed higher-dose tacrolimus arm with younger donors)
Number of subjects: 844
Study 29231428 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with catgut implantation
Number of subjects: 120
Study 29231428 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120
Study 29231428 — intervention group
Group type: COMPARATOR
Intervention: Catgut implantation
Number of subjects: 120
Study 25961367 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the diagnostic algorithm
Number of subjects: 441
Study 25961367 — intervention group
Group type: COMPARATOR
Intervention: Regular consultation by a doctor
Number of subjects: 441
Study 23452825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 20
Study 23452825 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study 21392712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium (HC) diet supplying 1,500 mg calcium/d
Number of subjects: 149
Study 21392712 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (UC)
Number of subjects: 149
Study 21392712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium (HC) diet
Number of subjects: 149
Study 19106155 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) during target vessel (TV) PCI
Number of subjects: 54
Study 19106155 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm RIPC in patients with single vessel disease
Number of subjects: 54
Study 19106155 — intervention group
Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 54
Study 17031767 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions (low-frequent, psycho-educative, supportive approaches)
Number of subjects: 715
Study 17031767 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 715
Study 15172393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach to statistical inference
Number of subjects: 0
Study 15172393 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach to statistical hypothesis testing
Number of subjects: 0
Study 10668706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu25-109 25 mg tid
Number of subjects: 496
Study 10668706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu25-109 50 mg tid
Number of subjects: 496
Study 10668706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu25-109 100 mg tid
Number of subjects: 496
Study 10668706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 9058328 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% doxycycline hyclate (DH)
Number of subjects: 180
Study 9058328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sanguinarium chloride (SC)
Number of subjects: 180
Study 9058328 — intervention group
Group type: COMPARATOR
Intervention: No agent (VC)
Number of subjects: 180
Study 8103953 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 171
Study 8103953 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 171
Study 30332285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixon T1-weighted MRI
Number of subjects: 58
Study 30332285 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbo inversion recovery magnitude MRI
Number of subjects: 58
Study 30332285 — intervention group
Group type: EXPERIMENTAL
Intervention: WB DWI MRI
Number of subjects: 58
Study 30332285 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced T1-weighted VIBE MRI
Number of subjects: 58
Study 27784410 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made mandibular repositioning device (MRDc)
Number of subjects: 25
Study 27784410 — intervention group
Group type: COMPARATOR
Intervention: Ready-made mandibular repositioning device (MRDr)
Number of subjects: 25
Study 27784410 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MRDc and MRDr
Number of subjects: 25
Study 25497480 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention/emotion skills and meditation training
Number of subjects: 76
Study 25497480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 23169319 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg SC abatacept weekly
Number of subjects: 646
Study 23169319 — intervention group
Group type: COMPARATOR
Intervention: 40 mg SC adalimumab biweekly
Number of subjects: 646
Study 21494062 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-session disorder-specific SAD treatment program including parent training and classical cognitive-behavioral therapy (CBT) components
Number of subjects: 43
Study 21494062 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 43
Study 17882417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5,000 U sub-Q daily)
Number of subjects: 42
Study 16177271 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational module explaining placebos in more depth
Number of subjects: 49
Study 16177271 — intervention group
Group type: COMPARATOR
Intervention: Routine explanation of placebos in the context of consent
Number of subjects: 49
Study 14504565 — intervention group
Group type: EXPERIMENTAL
Intervention: l-tryptophan
Number of subjects: 21
Study 14504565 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 10873185 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded compression stockings
Number of subjects: 98
Study 10873185 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 98
Study 9363277 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath vital capacity rapid inhalation induction (VCRII)
Number of subjects: 40
Study 9363277 — intervention group
Group type: COMPARATOR
Intervention: Multiple deep breaths inhalation induction (DBI)
Number of subjects: 40
Study 1489025 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (n = 11) with background infusion of 4 ml.h-1 of bupivacaine 0.125% with fentanyl 1 microgram.ml-1 and 3-6 ml bolus doses as required (15 min lockout interval)
Number of subjects: 23
Study 1489025 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion epidural analgesia (n = 12) with continuous infusion starting at 10 ml.h-1, adjustable up to 25 ml.h-1
Number of subjects: 23
Study 2872336 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup of ipecac 60 ml plus water 480 ml followed by activated charcoal 50 g
Number of subjects: 10
Study 2872336 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal 50 g
Number of subjects: 10
Study 29749641 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods
Number of subjects: 31
Study 29749641 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric control foods
Number of subjects: 31
Study 29749641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 27990505 — intervention group
Group type: EXPERIMENTAL
Intervention: GENESIS Implant System
Number of subjects: 53
Study 27990505 — intervention group
Group type: COMPARATOR
Intervention: PRIMA Implant System
Number of subjects: 53
Study 27990505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 53
Study 24928953 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor blockade (bosentan)
Number of subjects: 19
Study 24928953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24928953 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 19
Study 21048504 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 153
Study 21048504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 21048504 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide and Placebo
Number of subjects: 153
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA levels
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMA levels
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA/SDMA ratio
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine, IL-6, and CRP levels in ICU survivors
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA levels in ICU survivors
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMA levels in ICU survivors
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA/SDMA ratio in ICU survivors
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine, IL-6, TNF-alpha, CRP, and ADMA levels in non-survivors
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMA levels in non-survivors
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA/SDMA ratio in non-survivors
Number of subjects: 72
Study 20395894 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMA as a marker
Number of subjects: 72
Study 17324648 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 158
Study 17324648 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched women)
Number of subjects: 158
Study 15026508 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (10 Hz) for 20 minutes
Number of subjects: 60
Study 15026508 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study 11758896 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (Pulmicort Turbuhaler) 800 microg/day for 4 weeks
Number of subjects: 38
Study 11758896 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline (Talotren tablets, 200 mg twice daily) for 4 weeks
Number of subjects: 38
Study 9158315 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (lidocaine with sodium bicarbonate)
Number of subjects: 30
Study 9158315 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 30
Study 7964811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine 2 mg
Number of subjects: 16
Study 7964811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine 4 mg
Number of subjects: 16
Study 7964811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine 8 mg
Number of subjects: 16
Study 7964811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2890671 — intervention group
Group type: EXPERIMENTAL
Intervention: Piquindone (RO22‐1319)
Number of subjects: 37